Stryker Corp.: Consistent Growth
Diversification and acquisitions will help this maker of orthopedic devices continue to see its revenue grow.
Artificial joints are a multi-billion-dollar business that is expected to keep growing as the population ages and orthopedic products continue to evolve. The American Academy of Orthopedic Surgeons recently predicted that the number of hip replacements will nearly triple over the next 25 years.
That's good news for makers of joint replacements, including Stryker Corp. (symbol SYK), which has seen its revenue increase at a 15% compound rate over the last five years. But despite growing demand for orthopedic products, the industry is facing pressure from hospitals that want to cut the cost of orthopedic devices.
Some hospitals are considering banding together to switch to contracted vendors that offer bulk discounts. So far, these arrangements haven't gained footing, but reports predicting slowing growth in the orthopedic device sector have put a damper on stock prices.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Stryker's shares, currently $43, have fallen 9% this year. The company's price-earnings ratio has dropped quite a bit since 2004 -- another indication that the market is no longer knee-jerk enamored of the company.
Even if Stryker isn't able to raise its prices as much as it has in the past, the company's key advantage over competitors is diversification, says a report from Zacks Investment Research, which recently upgraded the stock to a "buy" rating. Of the major orthopedic manufacturers, Stryker is the least directly exposed to the implant market, with joint replacements making up only about a third of sales.
Stryker's other business segments are surgical equipment manufacturing and physical therapy services. In 2005, revenues from surgical-device sales increased 21%, while sales from physical therapy services grew 7%. It also has some research projects in the biotechnology area.
And Stryker adds to its portfolio of products through acquisitions. At the end of 2005, the company bought PlasmaSol, a producer of low-temperature sterilization equipment, for $17.5 million. In March, Stryker struck a $50 million deal to purchase Sightline Technologies, an Israel-based manufacturer of flexible endoscopes. The buying spree will likely continue. "Stryker's balance sheet is in excellent condition, so acquisitions are a constant possibility," says the Zacks report.
At $43, Stryker trades at 21 times estimated 2006 profits of $2.02 per share and 18 times estimated 2007 profits, according to Thomson First Call. Zacks' six-month price target for the stock is $53. In 2006, the company expects revenues to grow between 11% and 14% and predicts that earnings will grow at least 20%, its perennial target and the number that's made the company a favorite of growth-stock investors for a long time.
-- Katy Marquardt
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
-
7 Dr. Seuss Quotes Retirees Should Live ByYou're off to great places! Why Dr. Seuss is the retirement guru you didn't know you needed.
-
Fed's Rate Cuts Could Have Impacts You Might Not AnticipateUnderstanding how lower interest rates could impact your wallet can help you determine the right financial moves to make.
-
Past Performance Is Not Indicative of Your Adviser's ExpertiseMany people find a financial adviser by searching online or asking for referrals from friends or family. This can actually end up costing you big-time.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
-
What the Rich Know About Investing That You Don'tPeople like Warren Buffett become people like Warren Buffett by following basic rules and being disciplined. Here's how to accumulate real wealth.
-
If You'd Put $1,000 Into Bank of America Stock 20 Years Ago, Here's What You'd Have TodayBank of America stock has been a massive buy-and-hold bust.
-

If You'd Put $1,000 Into Oracle Stock 20 Years Ago, Here's What You'd Have TodayORCL Oracle stock has been an outstanding buy-and-hold bet for decades.
-
How to Invest for Rising Data Integrity RiskAmid a broad assault on venerable institutions, President Trump has targeted agencies responsible for data critical to markets. How should investors respond?
-
If You'd Put $1,000 Into Sherwin-Williams Stock 20 Years Ago, Here's What You'd Have TodaySherwin-Williams stock has clobbered the broader market by a wide margin for a long time.